MoonLake Immunotherapeutics Overview
Pro stress-test →MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases. The company develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company is advancing toward regulatory submissions with multiple late-stage clinical programs.
Strategic Profile
Pro stress-test →Founded in 2021 and headquartered in Zug, Switzerland, MoonLake is positioned as a pure-play developer of sonelokimab for immunologic dermatologic and rheumatologic diseases. The company secured up to $500 million in non-dilutive financing from Hercules Capital, extending cash runway into 2028. Strong analyst support and de-risked regulatory pathway support growth potential through 2026-2027 product launch.
Competitive Landscape
Pro stress-test →MoonLake competes in the IL-17 inhibitor space with established players like AbbVie (risankizumab), Eli Lilly, and emerging biotech companies. Sonelokimab's tri-specific mechanism targeting both IL-17A and IL-17F offers potential differentiation. The company addresses large indications (hidradenitis suppurativa, psoriatic arthritis) with significant unmet medical need and attractive market opportunities.
Industry Context
MoonLake Immunotherapeutics operates in Biopharmaceuticals - Clinical Stage / Immunotherapy.
Key facts
Founded: 2021 · Headquarters: Zug, Switzerland · Revenue: $0M · Market cap: $1.3B